Bio-Techne Co. (NASDAQ:TECH – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $81.00.
TECH has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft cut their price target on Bio-Techne from $85.00 to $82.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. Benchmark restated a “buy” rating and issued a $95.00 price target on shares of Bio-Techne in a research note on Thursday, May 2nd. Robert W. Baird lifted their price target on Bio-Techne from $73.00 to $81.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, Citigroup lowered Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 price target for the company. in a research note on Wednesday, May 22nd.
View Our Latest Analysis on Bio-Techne
Institutional Inflows and Outflows
Bio-Techne Stock Performance
NASDAQ TECH opened at $80.17 on Friday. The stock has a 50-day simple moving average of $76.25 and a two-hundred day simple moving average of $73.28. The firm has a market capitalization of $12.63 billion, a P/E ratio of 63.63, a PEG ratio of 8.59 and a beta of 1.29. Bio-Techne has a fifty-two week low of $51.79 and a fifty-two week high of $85.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.88 and a current ratio of 4.08.
Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. Bio-Techne had a return on equity of 13.60% and a net margin of 17.59%. The business had revenue of $303.43 million during the quarter, compared to analyst estimates of $292.36 million. During the same quarter last year, the business posted $0.47 EPS. The company’s revenue was up 3.2% on a year-over-year basis. On average, equities analysts forecast that Bio-Techne will post 1.56 earnings per share for the current year.
Bio-Techne Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Featured Stories
- Five stocks we like better than Bio-Techne
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Are Trending Stocks? Trending Stocks Explained
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- What is the FTSE 100 index?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.